In the same period, the company’s exports stagnated at RON80 million.
In 2012, the company reported a RON420 million turnover on the local market and RON80 million exports.
In 2014, Damian targets up to 15% exports growth, and a 10% sales growth for the local and foreign market.
The company’s main export markets are Russia, Ukraine, the Commonwealth of Independent States, and EU.
This year, Terapia Ranbaxy plans to launch 12 new products and also has a RON25 million investments budget. Last November, the company announced it will start an investment in a RON30 million research center for the production of new generic drugs, partially funded via European funds.
Ranbaxy Laboratories, the largest drug maker in India, bought 96.7% of Terapia Cluj-Napoca in March 2006 from investment fund Advent International for $324 million. In 2008, Japanese pharmaceutical group Daiichi Sankyo became the majority shareholder of Ranbaxy Laboratories. (EUR1=RON4.4824)